Lymphoma is the most common type of blood cancer and it is caused by abnormal growth and reproduction of white blood cells called lymphocytes. Patients are more likely to be older than age 60; men and women equally. It usually manifests first with swollen but painless lymph nodes. Prognosis can be encouraging for the more common non-Hodgkin’s lymphoma.
Where To Find Information On Lymphoma Clinical Trials
There are two main sources for information about lymphoma clinical trials, according to the Lymphoma Research Foundation, the largest non-profit organization in the country devoted exclusively to funding innovative lymphoma research and providing public information.
The website at National Institutes of Health (NIH), sponsored by the National Library of Medicine and the NIH, and includes hundreds of lymphoma trials. Another website at the National Cancer Institute (NCI) also lists lymphoma clinical trials.
Additionally, clinicaltrials.gov operated by the U.S. government, lists all clinical trials worldwide for lymphoma and other diseases. While the lists are comprehensive, the search function and information presented has been reported to be less user-friendly than sites managed by advocacy groups.
To participate in a lymphoma clinical trial, patients must fulfill requirements regarding age, sub-type of lymphoma and stage, previous types of treatments, timing, response, and overall health condition.
Other characteristics like geographic area may also be required. Hundreds of clinical trials are currently taking place in hospitals, cancer centers and laboratories nationwide. Prior to applying or accepting participate in a study, it is important for patients to carefully read the clinical trial’s fact sheet and all information provided.
Current Notable Lymphoma Clinical Trials:
- “Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma” will be developed with support from the M.D. Anderson Cancer Center and is currently recruiting patients.
- “Molecular and Whole-body MR Imaging in Lymphomas (MILY)” to be conducted at the Turku University Hospital is currently recruiting patients.
- “Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters” is a study recruiting patients to be performed at the Fondazione Italiana Linfomi ONLUS.
- “Idiotypic Vaccination for Follicular Lymphoma Patients” is also recruiting patients to be initiated in the Clinica Universidad de Navarra, Universidad de Navarra, in Spain.
- “Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas” is also recruiting patients to be conducted at the University of Chicago, with the collaboration of the National Cancer Institute.
- “Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)” has already finished recruitment and is ongoing at the Celgene Corporation.
- “Imexon for Relapsed Follicular and Aggressive Lymphomas” has already presented some results, but the research being conducted in collaboration between the University of Rochester and the University of Arizona is not completed yet.
- “Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma” has already been completed with sponsorship of AIDS Malignancy Consortium and collaboration of the National Cancer Institute and the EMMES Corporation.
- “An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn’s Disease” is already completed, with sponsorship of Centocor Ortho Biotech Services, L.L.C.
- “Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma” has been completed with sponsorship of the AIDS Malignancy Consortium and collaboration of the National Cancer Institute and the EMMES Corporation.
For lymphoma clinical trials currently recruiting patients, log on clinicaltrials.gov